Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.57 |
| ▸ | SLC6A9 | P48067 | 4/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.52 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.48 |
| ▸ | LMNA | P02545 | 3/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | KIT | P10721 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | CKS1B | P61024 | 1/20 | 0.44 |
| ▸ | SKP1 | P63208 | 1/20 | 0.44 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.44 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31027289 | 1.00 | MEN1 (0.57) | MEN1KMT2ASLC6A9KCNH2GPR119 | |
| SCHEMBL30851276 | 0.89 | MEN1 (0.61) | MEN1KMT2ASLC6A9GPR119SMN1; SMN2 | |
| SCHEMBL2365916 | 0.89 | MEN1 (0.61) | MEN1KMT2ASLC6A9GPR119SMN1; SMN2 | |
| SCHEMBL31410416 | 0.88 | KMT2A (0.57) | MEN1KMT2AGPR119SMN1; SMN2LMNA | |
| SCHEMBL31410432 | 0.88 | KMT2A (0.57) | MEN1KMT2AGPR119SMN1; SMN2LMNA | |
| SCHEMBL31410510 | 0.87 | MEN1 (0.56) | MEN1KMT2AGPR119SMN1; SMN2LMNA | |
| SCHEMBL14598673 | 0.87 | MEN1 (0.56) | MEN1KMT2AGPR119SMN1; SMN2LMNA | |
| SCHEMBL30940692 | 0.87 | MEN1 (0.56) | MEN1KMT2AKCNH2GPR119SMN1; SMN2 | |
| SCHEMBL31142882 | 0.87 | KMT2A (0.76) | MEN1KMT2ASMN1; SMN2LMNAMAPT | |
| SCHEMBL2366233 | 0.87 | KMT2A (0.76) | MEN1KMT2ASMN1; SMN2LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023139536-A1 | (4-PIPERAZIN-1YL)-4-ALKYL-PHTHALAZIN-1(2H)-ONE COMPOUNDS AS PARP7 INHIBITORS | RHIZEN PHARMACEUTICALS AG (CH) | 2023-07-27 | — | — | WO | disclosed |
| CN-115745971-A | PARP7 inhibitor and application thereof | 重庆华森制药股份有限公司 | 2023-03-07 | — | — | CN | disclosed |
| US-20210246140-A1 | MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2 | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-08-12 | — | — | US | disclosed |
| US-20210246140-A1 | MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2 | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-08-12 | — | — | US | disclosed |
| WO-2021155196-A1 | MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2 | THE GENERAL HOSPITAL CORPORATION (US) | 2021-08-05 | — | — | WO | disclosed |
| US-20080287455-A1 | SULFANYL SUBSTITUTED PHENYL METHANONES | JOLIDON SYNESE | 2008-11-20 | — | — | US | disclosed |
| US-20080287455-A1 | SULFANYL SUBSTITUTED PHENYL METHANONES | JOLIDON SYNESE | 2008-11-20 | — | — | US | disclosed |
| US-20080287455-A1 | SULFANYL SUBSTITUTED PHENYL METHANONES | JOLIDON SYNESE | 2008-11-20 | — | — | US | disclosed |
| EP-1836178-A1 | SULFANYL SUBSTITUTED PHENYL METHANONES AS GLYCINE TRANSPORTER 1 (GLYT-1) INHIBITORS FOR THE TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS | F. Hoffmann-Roche AG (CH) | 2007-09-26 | — | — | EP | disclosed |
| WO-2006072435-A1 | SULFANYL SUBSTITUTED PHENYL METHANONES AS GLYCINE TRANSPORTER 1 (GLYT-1) INHIBITORS FOR THE TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS | F.HOFFMANN-LA ROCHE AG (CH) | 2006-07-13 | — | — | WO | disclosed |
| US-20060149062-A1 | Sulfanyl substituted phenyl methanones | F. HOFFMANN-LA ROCHE AG (CH) | 2006-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060149062-A1 | Sulfanyl substituted phenyl methanones | SULT1A1, SULT2A1, SULT1E1 | MEN1 1766/4885KMT2A 1819/4885SLC6A9 19/4885 |
| US-20210246140-A1 | MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2 | GRM1, GRM2, GRIN1 | MEN1 2621/4885KMT2A 1106/4885SLC6A9 235/4885 |
| US-20080287455-A1 | SULFANYL SUBSTITUTED PHENYL METHANONES | SULT1A1, SULT2A1, SULT1E1 | MEN1 1766/4885KMT2A 1819/4885SLC6A9 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.